US nod for Novartis’ breast cancer drug Kisqali
Novartis’ selective cyclin-dependent kinase inhibitor Kisqali has been approved by the US Food and Drug Administration as a treatment for patients with a certain form of breast cancer.
Read More
Tag: LEE011
Novartis’ breast cancer drug ribociclib gets US, EU review
Novartis’ experimental selective cyclin dependent kinase inhibitor LEE011 (ribociclib) is now under review on both sides of the Atlantic as a potential treatment for breast cancer.
Read More
US breakthrough status for Novartis’ breast cancer drug
Novartis’ experimental selective cyclin dependent kinase inhibitor LEE011 (ribociclib) has picked up a Breakthrough Therapy designation in the US for the treatment of certain forms of breast cancer.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
